Skip to Main Content

Paper Details

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Leukemia
41
2021
ALL, Children, FLT3, FLT3i, FLTi, Infants, KMT2A, KMT2A-r ALL, KMT2A-rearranged acute lymphoblastic leukemia, Patient, acute lymphoblastic leukemia, blasts, infant, infants, lestaurtinib, leukemia blasts, leukemic, patients, r
Author NameAffiliation
Patrick BrownSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Patrick BrownSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Meenakshi DevidasSt. Jude Children's Research Hospital
Donald SmallSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Donald SmallSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Mignon L LohBenioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
Stephen P HungerDepartment of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania
Stephen P HungerDepartment of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania
  • 1 - 8

Datasets

Release 1.2